Skip to main content
Clinical Trials/NCT02550847
NCT02550847
Unknown
Not Applicable

Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer

National Taiwan University Hospital1 site in 1 country100 target enrollmentAugust 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pancreatic Cancer
Sponsor
National Taiwan University Hospital
Enrollment
100
Locations
1
Primary Endpoint
The tumor recurrence rate after operation at 6 months
Last Updated
10 years ago

Overview

Brief Summary

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Detailed Description

The results of MR/PET will be compared prospectively to dedicated MDCT or MR imaging, pathologic results, and clinical outcomes to assess the value of MR/PET in pancreatic cancers.

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
August 2016
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosed as pancreatic cancer
  • Between 20\~90 years old
  • Normal renal function
  • Measurable tumor size (\>1cm)

Exclusion Criteria

  • Contraindication for MRI exam
  • Claustrophobia
  • Renal insufficiency
  • Other malignancy
  • Pregnancy and lactating women

Outcomes

Primary Outcomes

The tumor recurrence rate after operation at 6 months

Time Frame: 6 months

Secondary Outcomes

  • The overall survival after operation at 6 months(6 months)

Study Sites (1)

Loading locations...

Similar Trials